• LAST PRICE
    1.8058
  • TODAY'S CHANGE (%)
    Trending Up0.1158 (6.8521%)
  • Bid / Lots
    1.7700/ 2
  • Ask / Lots
    1.8100/ 20
  • Open / Previous Close
    1.7400 / 1.6900
  • Day Range
    Low 1.7400
    High 1.8800
  • 52 Week Range
    Low 0.9670
    High 3.1399
  • Volume
    32,669
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 27, 2024

  • Nov 12, 2024

  • Nov 8, 2024

      Show headlines and story abstract
    • 7:05AM ET on Friday Nov 08, 2024 by Dow Jones
      Companies Mentioned: APYX

      Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering

      CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion(R), today announced it has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the Company's common stock at a purchase price of $1.18 per share and pre-funded warrants to purchase up to 2,934,690 shares of the Company's common stock at a purchase price of $1.179 per pre-funded warrant (which represents the per share offering price for common stock less the exercise price per share for each pre-funded warrant of $0.001). The gross proceeds to Apyx Medical from the offering were approximately $7,000,000, before deducting offering expenses payable by the Company. The offering closed on November 8, 2024.
    • 7:02AM ET on Friday Nov 08, 2024 by MT Newswires
      Companies Mentioned: APYX
      07:02 AM EST, 11/08/2024 (MT Newswires) -- ...
    • 7:00AM ET on Friday Nov 08, 2024 by Dow Jones
      Companies Mentioned: APYX
      (Unaudited) December 31, 2023 ---------------------- --------------------- ASSETS Current assets: Cash and cash equivalents $ 28,013 $ 43,652 Trade accounts receivable, net of allowance of $750 and $608 13,036 14,023 Inventories, net of provision for obsolescence of $930 and $875 9,000 9,923 Prepaid expenses and other current assets 2,109 2,764 -------------- -------------- Total current assets 52,158 70,362 Property and equipment, net of accumulated depreciation and amortization of $3,889 and $3,522 1,905 1,915 Operating lease right-of-use assets 4,820 5,162 Finance lease right-of-use assets 53 69 Other assets 1,785 1,732 -------------- -------------- Total assets $ 60,721 $ 79,240 ============== ============== LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 1,914 $ 2,712 Accrued expenses and other current liabilities 7,291 9,661 Current portion of operating lease liabilities 330 347 Current portion of finance lease liabilities 20 20 -------------- -------------- Total current liabilities 9,555 12,740 Long-term debt, net of debt discounts and issuance costs 33,853 33,185 Long-term operating lease liabilities 4,606 4,896 Long-term finance lease liabilities 38 53 Long-term contract liabilities 1,271 1,246 Other liabilities 201 198 -------------- -------------- Total liabilities 49,524 52,318 EQUITY Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of September 30, 2024 and December 31, 2023 -- -- Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,926 issued and outstanding as of September 30, 2024, and 34,643,888 issued and outstanding as of December 31, 2023 35 35 Additional paid-in capital 84,289 81,114 Accumulated deficit (73,283) (54,448) -------------- -------------- Total stockholders' equity 11,041 26,701 Non-controlling interest 156 221 -------------- -------------- Total equity 11,197 26,922 -------------- -------------- Total liabilities and equity $ 60,721 $ 79,240 ============== ==============

Peers Headlines